Intellia Therapeutics (NASDAQ:NTLA) and Neurogene (NASDAQ:NGNE) Critical SurveyDefense World · 4 days ago
Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual CongressBusiness Wire · 5 days ago
Neurogene (NASDAQ:NGNE) Sees Large Volume Increase – Should You Buy?Defense World · Oct 12, 2026
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire · Oct 5, 2026 Head-To-Head Comparison: Neurogene (NASDAQ:NGNE) & Applied Dna Sciences (NASDAQ:BNBX)Defense World · Sep 25, 2026
Bank of New York Mellon Corp Purchases New Position in Neurogene Inc. $NGNEDefense World · Sep 11, 2026Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$1.42 | -$1.53 | Miss |
| May 12, 2026 | -$1.30 | -$1.39 | Miss |
| Mar 24, 2026 | -$1.24 | -$1.12 | Beat |
| Nov 14, 2025 | -$1.26 | -$0.99 | Beat |
| Aug 11, 2025 | -$1.15 | -$1.05 | Beat |
| May 9, 2025 | -$1.05 | -$1.08 | Miss |